Our systems - We produce highly intelligent, multifunctional, mesoporous silica micro and nano-systems to be exploited in target therapy
Why choosing our systems - Our system allow to obtain high therapeutic efficacy, lacking toxicity and side effects
Rapidly expanding market - The market for drug delivery systems will grow from $ 11.3 billion registered in 2012 to $ 30.9 billion estimated for 2017
The mesoporous silica micro- and nano-particles are ideal candidates for the development of systems for target drug delivery , because they are easily synthesized , versatile , biocompatible and soluble in biological fluids.
NanoSiliCal Devices is a spin-off at the University of Calabria and an innovative start-up , founded in 2014; it aims to develop nanostructured products that may be exploited as smart anticancer therapies.
Biotechnology market shows a growing trend and it will further increase in the next years. The highly innovative technologies offered by NanoSiliCal Devices might be a very important opportunity to potential investors, collaboration partners and licensees from the international biopharmaceutical industry.
Our products technology is based on science of materials, providing nanostructured particles that can be administered intravenously, and, through the bloodstream, they can reach cancer cells, interact with them through a biological process and release a drug within. This leads to reduction of therapeutic doses, with a consequent therapeutic efficacy improvement and without toxic and side effects.
Mesoporous silica-based nanodevices (MSN) bearing a targeting molecule on the outer surface and an antineoplastic pro-drug linked within the pores by means of a pH-sensitive bond, as vehicles for targeting and release of biologically active molecules, are developed to be employed in targeted therapy. Suitable nanostructuring of matter better than with polymers because of nanoarchitecture and surface reactivity. Their pH-sensitive bond provides pro-drug (a biologically inactive form) delivery through the bloodstream (pH 7.4), until nanosystems reach the target tissue (pH 4-5), where they release the active form of the drug.
Mesoporous silicas micro- or nanosystems anchored, through an avidin group, to a biotin-linked specific molecule (such as a monoclonal antibody, directed against a tumor marker). The system, conjugated to a drug with pH sensitive release control, is able to promote a ligand-mediated internalization into cells, causing their death.
Mesoporous silicas micro- or nano-systems linked with a highly specific ligand and a fluorescent marker that allows the visualization of target cells.
Mesoporous silicas micro- or nanosystems coupled to a specific functional group and with pores able to include plasmidic DNA, coding for proteins that have to be expressed in cellular systems (e.g. in basic experimental research), or in a specific organism, in case of deficits associated to a particular disease (gene therapy).
More information Publications
Dr Luigi Pasqua, NanoSiliCal Devices' CEO, explains research and development innovative activities of our company.